P1/2, N=78, Completed, Heron Therapeutics | Phase classification: P1b/2 --> P1/2

Leveraging clinical feasible RNA-seq and TMB analysis, our model exhibits robust predictive efficacy of ICB response in multiple cancers, enabling subtype-tailored therapeutic combinations to improve immunotherapy response.

The system is constructed using celecoxib (CXB)-loaded poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles and subsequently camouflaging them with mesenchymal stem cell membranes with high CXCR4 expression...This dual modulation of the chemokine network significantly improves the therapeutic efficacy of CAR-T cells against solid tumors. Our approach represents a promising strategy for advancing CAR-T cell therapy toward clinical applications for soild tumors.

P3, N=209, Completed, Heron Therapeutics | Phase classification: P3b --> P3 | N=115 --> 209

By integrating genetic causal inference, in vitro experiments, and network pharmacology, our study systematically reveals that celecoxib may exert therapeutic effects by targeting against cervical cancer by targeting NEU1 and modulating CD25 on CD45RA+ CD4+ non-regulatory T cell-related immune pathways. This finding highlights both the novelty and the translational potential of this approach.

P2/3, N=58, Terminated, Wake Forest University Health Sciences | N=100 --> 58 | Suspended --> Terminated; Study initially suspended following an audit and need of amendment to address deficiencies. PI requested to terminate due to lack of support.

P2/3, N=80, Not yet recruiting, Odense University Hospital

This study provides a diagnostic model for osteosarcoma metastasis and proposes that MYC/TNFRSF21 drive metastasis via a "necroptosis‑immune exemption" axis, suggesting new therapeutic strategies.

Moreover, intervention with the PTGS2 inhibitor celecoxib counteracted the tumor-promoting functions of OTX1 and demonstrated tumor-suppressive effects in in vivo OS models. Herein, results demonstrate that OTX1 drives OS malignant progression by transcriptionally activating PTGS2, which in turn modulates apoptosis- and invasion-related molecules. Targeting the OTX1/PTGS2 axis may represent a promising therapeutic strategy for OS, particularly in high-risk patients with aberrant OTX1 expression.

Tailored for the TNBC postoperative setting, we developed a photopolymerizable, dual-asymmetric hemostatic Janus hydrogel patch (DJ-Patch) based on the synergistic pharmacodynamic rationale of gambogic acid (GA) and celecoxib (CXB) pairing...In an orthotopic 4T1-Luc TNBC resection model, the DJ-Patch achieved 86% survival, complete tumor clearance by day 7, and suppressed lung metastasis through sustained COX-2/PGE2 axis inhibition, Treg cell reduction, and remodeled the immunosuppressive tumor microenvironment (TME). Collectively, this integrated platform offers a promising strategy for comprehensive TNBC postsurgical management.

Compound A is an analog of the cyclooxygenase-2 (COX-2) inhibitor Nimesulide. Pharmacokinetic studies reveal that compound A has a half-life (t 1/2) of 3.11 h and a BBB penetration of 52%, which is even higher than the standard chemotherapy Temozolomide. These results suggest that the AR degrader has great potential as a novel GBM treatment.

NSI-5 exerted the highest anti-leukemic activity among these sulindac analogs, as determined at a sub-micromolar level in all cell lines studied, by IC50...Collectively, these findings indicate that NSI-5 is a promising in vitro anti-leukemic lead compound, with activity associated with mitochondrial dysfunction and altered redox regulation. The observed effects are consistent with previously reported COX-independent activity of structurally related NSAID derivatives, and support further investigation of NSI-5 in preclinical models.